Entera Bio Ltd. (ENTX)
Company Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs.
The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.
The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.
Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Country | IL |
| IPO Date | Jun 28, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Miranda J. Toledano M.B.A. |
Contact Details
Address: Kiryat Hadassah Minrav Building Jerusalem, IL | |
| Website | https://www.enterabio.com |
Stock Details
| Ticker Symbol | ENTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638097 |
| CUSIP Number | M40527109 |
| ISIN Number | IL0011429839 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Miranda J. Toledano M.B.A. | Chief Executive Officer & Director |
| Dana Yaacov-Garbeli CPA | Chief Financial Officer |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer |
| Dr. Gregory Burshtein Ph.D. | Chief of Research & Development |
| Leslie Gautam | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 06, 2025 | 424B3 | Filing |
| Jun 05, 2025 | DEFA14A | Filing |
| Jun 05, 2025 | ARS | Filing |
| Jun 05, 2025 | DEF 14A | Filing |
| May 30, 2025 | S-8 | Filing |
| May 30, 2025 | S-3 | Filing |
| May 20, 2025 | 3 | Filing |
| May 14, 2025 | PRE 14A | Filing |
| May 09, 2025 | 10-Q | Quarterly Report |
| May 09, 2025 | 8-K | Current Report |